Tools for Practice Outils pour la pratique


#113 Acetaminophen in pregnancy and future risk of ADHD for the unborn.


CLINICAL QUESTION
QUESTION CLINIQUE
Does acetaminophen in pregnancy increase the future risk of Attention Deficit Hyperactive Disorder (ADHD) for the unborn?


BOTTOM LINE
RÉSULTAT FINAL
Two well-done cohort studies suggest an association between acetaminophen use in pregnancy and an increased risk of ADHD or similar behaviours in children. While cohort studies cannot prove causation and we need further confirmation, there may be a possible small risk of prolonged use of acetaminophen – especially late in pregnancy. Study limitations prevent specifics.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Three cohort studies:  
  • Danish prospective cohort of 64,322 pregnancies.1 Acetaminophen use in pregnancy associated with statistically significantly: 
    • Higher scores for behavioural problems on the Strengths & Difficulties Questionnaire (at seven years): Risk Ratio 1.13 (1.01-1.27). 
    • From a government central registry (over ~11 years):  
      • Diagnosed hyperkinetic disorder: Hazard Ratio 1.37 (1.19-1.59). 
      • Prescription of ≥2 ADHD medicationsHazard Ratio 1.29 (1.15-1.44) 
  • Norwegian prospective cohort of 48,631 pregnancies.2 Focus on 2,919 same-sex sibling pairs:  
    • Acetaminophen use ≥28 days in pregnancy correlated significantly with maternally-assessed child behaviour at three years for: 
      • Reduced gross motor skills, delay in walking, increased activity, reduced communication skills, attention/aggression behaviours. 
      • Correlation Beta-coefficients around 0.2-0.26, approximately equivalent to a 50-60% relative increase.   
    • Strength: Sibling pairs (eliminating differences in mother/families).  
    • Weakness: Shorter duration and only maternal assessment. 
  • Both studies suggest (results inconsistent) longer use and use later in pregnancy may have stronger association.1,2 
  • Older cohort of 355 children found no association between maternal use of acetaminophen in the first five months of pregnancy and attention testing at age four.3
Context:  
  • Cohort studies show associations (things happening together) but not causation.   They are subject to confounding’ risk.  
    • Women who used acetaminophen may be different: having more pain or headaches and perhaps this contributes to ADHD.  
  • Based on 5.3% worldwide prevalence of ADHD4 and a possible 13-37% relative increase,1 absolute increase might be 0.7%-2%, if real.   
  • Acetaminophen is used by 55-65% of pregnant women.1,5,6  
  • Acetaminophen is generally felt to be safe in pregnancy7 (not teratogenic) and recommended first-line for pain due to safety.8,9   
    • These statements precede this recent research.  


Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Jill A Blaser MSc MD CCFP

1. Liew Z, Ritz B, Rebordosa C, et al. JAMA Pediatr. 2014; 168(4):313-20.

2. Brandlistuen RE, Ystrom E, Nulman I, et al. Int J Epidemiol. 2013; 42(6):1702-13.

3. Streissguth AP, Treder RP, Barr HM, et al. Teratology. 1987; 35(2):211-9.

4. Polanczyk G, de Lima MS, Horta BL, et al. Am J Psychiatry. 2007; 164(6):942-8.

5. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Pharmacoepidemiol Drug Saf. 2013; 22(9):1013-8.

6. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. Am J Obstet Gynecol. 2005; 193(3 Pt 1):771-7.

7. Scialli AR, Ang R, Breitmeyer J, et al. Reprod Toxicol. 2010; 30:495-507.

8. Babb M, Koren G, Einarson A. Treating pain during pregnancy. Mother Risk. 2010. Available at: http://www.motherisk.org/prof/updatesDetail.jsp?content_id=922 . Accessed April 24, 2014.

9. Clemente-Fuentes RJ, Pickett H, Carney M. J Fam Pract. 2013; 62:260-8.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.